Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week
A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The trades have taken place between February 18, 2025 and February 21, 2025. • JPMorgan Chase (NYSE:JPM) disclosed a series of transactions this week.
Bristol Myers Squibb GC to Retire After 33 years With Drugmaker
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make decisions quickly and to be accountable for those decisions."
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.
Bristol-Myers Squibb (BMY) Receives a Buy from Truist Financial
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s
Bristol Myers Squibb Lights the Way to Treasury Innovation
For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with Celgene in one of the biggest acquisitions in pharmaceutical history, the company’s treasury team needed to regroup.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 6,117.
Bristol-Myers Squibb (BMY) Gets a Hold from Bernstein
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of
2BMY : Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...
Bristol Myers Gets Speedy FDA Review of Opdivo/Yervoy Combo in Certain Colorectal Cancer Patients
Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...
Contract Pharma6h
FDA Accepts Bristol Myers Squibb’s sBLA for Opdivo Plus Yervoy
The application was based on results from the three-arm Phase 3 CheckMate -8HW study.
Bristol Myers Squibb Names New GC as Legal Chief Retires
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
GlobalData on MSN7d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Zacks Research Issues Pessimistic Estimate for BMY Earnings
Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a note ...
Hosted on MSN3d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Pharmabiz2d
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...